RecruitingNCT06043193

Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.


Sponsor

Hospices Civils de Lyon

Enrollment

100 participants

Start Date

Feb 20, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The study consists of having participants complete quality of life questionnaires (PROMs) at the time of the cures +/- one week and in the middle of the intercure time +/- one week. As all the collection times do not correspond to a consultation or a visit to a medical service, The investigator wanted to develop a remote, computerized data collection solution. Researchers have programmed an AURA-RIV-TNE care pathway (MOCAs: Engine for the organization and coordination of health acts) on the myHCL patient environment, taking up the course of the study presented in the form of a table in paragraph 6.2. Once the patient consents to participate in the study, he must create an account on the patient interface of his investigation center (myHCL, myCHUGA etc) as much as possible to facilitate data extraction. Once the patient consents to participate in the study, the MOCAs AURA-RIV-TNE course will be associated with him in the Easily software, by defining the date week 0 (baseline) of the first treatment. This will allow automated sending of MAIL and SMS reminders at each questionnaire time. The MAILs will contain an internet link allowing the participant to be directly written to the questionnaires to be completed. A reminder system will be possible if the patient does not complete the questionnaire.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Age >18 years;
  • Patient starting treatment with RIV validated in the RENATEN RCP;
  • Patient having received written information about the study;
  • Collection of the patient's non-objection
  • Patients for whom treatment with RIV is administered within the framework of a clinical trial, may be included in the AURARIV-TNE study according to the written indications written in the 2 nd protocol of the sponsor of the clinical trial;
  • Patients undergoing re-treatment with RIV can be included;

Exclusion Criteria2

  • Persons deprived of their liberty by a judicial or administrative decision;
  • Adults subject to a legal protection measure (guardianship, curatorship);

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(4)

CHU de Saint-Etienne, Hôpital Nord

Saint-Priest-en-Jarez, Saint-Etienne, France

CH Métropole Savoie

Chambéry, France

Centre de Lutte Contre le Cancer Jean Perrin

Clermont-Ferrand, France

Hospices Civils de Lyon, Hopital Lyon Sud

Lyon, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06043193